COVID-19 Vaccine – Is the pandemic nightmare coming to an end?

Last week, Pfizer announced that the effectiveness of the COVID-19 vaccine was 90%. The company will apply for a license to launch in the second half of November this year. This information made US and global stocks soar. However, the American press has a more realistic view.

No one can deny that vaccines are the key to reopening the economy, so as soon as the Pfizer vaccine news was released, CNBC said, “The positive news about vaccines is very motivating. essential for economic prospects “.

According to the article, this information provides the expectation that the COVID-19 nightmare, if not an end, will also reduce its carnage. This is beneficial for the US economy, as economic activities will return to normal sooner.

However, some economists are skeptical that the impact of the vaccine on the economy will be less than expected. Mark Zandi – Chief Economist of Moody’s Analytics, said the pandemic will continue to cause difficulties for businesses for at least 2 to 3 months.

Volunteer to test Pfizer’s COVID-19 vaccine at the Medical School, University of Maryland, Baltimore, May 2020 (Image: NY Times)

The concerns of economists are justified, because of the vaccination implementation difficulties that the New York Times pointed out in an article titled “Pfizer plans to distribute its vaccines as In particular, the federal government and US states are not currently planning how to distribute the vaccine and who will be the priority target.

Not only that, the Pfizer vaccine must be kept in a temperature of minus 70 degrees C, requiring certain preparation of suitable storage and transportation equipment.

Staff in health facilities also need to be trained to ensure that those who get the first shot return to the second one four weeks later, most importantly convincing people to vaccinate in the context of the movement. Vaccine boycott is still very strong.

The Wall Street Journal reported that even with approval in November, by the end of this year, Pfizer could only produce up to 50 million doses of vaccine. And from 2021 it is about 1.3 billion doses per year, far less than global demand, not to mention how much of that will be delivered in the US. Therefore, the state governments cannot immediately remove all restrictions. And so, the recovery of the US economy will still take time.